Industry is less inclined to expand investment this year
By Kim, Jin-Gu | translator Kim, Jung-Ju
24.01.03 05:50:52
가나다라
0
[New Year's Feature] Pharmaceutical & Bio Industry CEO Survey ③2024 Management Strategy
Survey of 53 Pharma CEOs...53% of which responded that they will "expand investment” last year, as compared to the 25% this year
Management priorities the managers align in order of new product launch>R&D investment>Sales power reinforcement>Production capacity expansion
One in four CEOs of pharma and biotech companies announced that they will expand their investment in 2024.
This is down by half compared to the response received in the survey last year when one in two CEOs said they would expand investment. This is likely a reflection of the growing economic uncertainty in Korea and abroad.
1 in 4 CEOs "will expand investment"...half of last year's level
According to the 2024 Business Management Strategy Survey Dailpharm conducted for 2024 on 53 CEOs of pharma and biotech companies, 25% (13 respondents) responded that they plan to expand investments this year compared to the previous year.
68% (36 out of 53)
Kim, Jin-Gu(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)